Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STING-NP is a nanoparticle-based immunotherapy designed to activate the Stimulator of Interferon Genes (STING) pathway. It consists of polymer vesicles (polymersomes) engineered for the efficient cytosolic delivery of 2’3’ cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), an endogenous cyclic dinucleotide (CDN) ligand. By overcoming the delivery barriers of free CDNs—such as poor membrane permeability and rapid enzymatic degradation—STING-NP enhances the activation of innate immunity within the tumor microenvironment. Preclinical studies, particularly in murine melanoma models, have shown that intratumoral administration of STING-NP increases tumor immunogenicity and works synergistically with immune checkpoint inhibitors (anti-PD-1/CTLA-4) to promote systemic anti-tumor responses and overcome immune escape mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on STING-NP.